Best Hospitals for Breast Cancer Treatment in Dubai, UAE

Breast cancer arises from malignant transformation of epithelial cells lining the mammary ducts (ductal carcinoma, comprising ~80% of cases) or lobules (lobular carcinoma). At the molecular level, tumors are stratified by receptor status — Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) — as well as by genomic subtypes (Luminal A, Luminal B, HER2-enriched, Triple-Negative), each carrying distinct prognostic implications and dictating entirely different therapeutic algorithms. Locally advanced and metastatic disease may involve lymphovascular invasion, axillary node involvement, or distant spread to bone, lung, liver, or brain, requiring systemic therapy in addition to locoregional control.

• ELIGIBLE PATIENTS:
• Women and men with histologically confirmed breast carcinoma (core-needle biopsy or excision biopsy with immunohistochemistry confirming ER/PR/HER2 status)
• Patients across all clinical stages (Stage I–IV) seeking definitive treatment, second opinions, or continuation of systemic therapy
• Patients with locally recurrent breast cancer after prior treatment
• High-risk individuals (BRCA1/BRCA2 pathogenic variants, strong family history) seeking risk-reducing prophylactic mastectomy
• +19 more

Surgical APPROACHES:

1. Breast-Conserving Surgery (BCS / Lumpectomy with Oncoplastic Techniques): Removal of the tumor with clear surgical margins (minimum 2 mm for invasive carcinoma, no ink on tumor for DCIS per SSO-ASTRO guidelines) combined with oncoplastic volume displacement or replacement techniques to maintain breast aesthetics. Sentinel lymph node biopsy (SLNB) using dual-tracer technique (Technetium-99m radiocolloid + Patent Blue V dye, or increasingly indocyanine green fluorescence-guided) has replaced routine axillary lymph node dissection (ALND) in clinically node-negative patients, dramatically reducing lymphedema rates. BCS is invariably followed by adjuvant whole-breast irradiation.

2. Nipple-Sparing Mastectomy (NSM) and Skin-Sparing Mastectomy (SSM): Gold-standard procedures for patients requiring total mastectomy, particularly those seeking immediate reconstruction. Preservation of the nipple-areola complex (NAC) is oncologically safe in appropriately selected patients (tumor >2 cm from NAC, no Paget's disease, negative sub-areolar margin on frozen section). Robotic-assisted nipple-sparing mastectomy (using the da Vinci Xi system) is now offered at select centers in India (Tata Memorial, Apollo, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital), enabling smaller incisions, enhanced 3D visualization, and reduced skin flap trauma.

3. Modified Radical Mastectomy (MRM): Removal of the entire breast with overlying skin plus Level I–II axillary lymph node dissection. Indicated for locally advanced disease, inflammatory breast cancer, or when immediate reconstruction is not feasible.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel):

• Patient submits existing biopsy reports, imaging (mammogram, MRI, PET-CT), and blood work to GAF Healthcare's oncology case management team
• GAF Healthcare facilitates a secured video consultation with the treating surgical oncologist, medical oncologist, and reconstructive surgeon at the chosen destination
• Multidisciplinary Tumor Board review is conducted; a personalized treatment plan with staging, modality sequence, and timeline is prepared
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; all hospital appointment scheduling and pre-admission paperwork completed remotely
• Patient arranges travel insurance with oncology treatment coverage as advised by GAF

PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5):